Interventions to reduce antipsychotic polypharmacy: A systematic review

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 215-220

  Tani, Hideaki ^a,b   Uchida, Hiroyuki ^b,c   Suzuki, Takefumi ^b,d   Fujii, Yasuo ^a   Mimura, Masaru ^b  

^a Yamanashi Prefectural University   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Inokashira Hospital   (Japan)

Author keywords

Antipsychotic; Intervention; Polypharmacy; Schizophrenia

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; RISPERIDONE;

DRUG SUBSTITUTION; DRUG TOLERABILITY; HUMAN; MENTAL PATIENT; MONOTHERAPY; OPEN STUDY; PATIENT EDUCATION; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; SCHIZOPHRENIA;

EID: 84871937726     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.015     Document Type: Review

References (47)

1. American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia 2004, APA, Washington, D.C., (http://www.psych.org/). second edition.
2. Argo T., Crismon M., Miller A., Moore T. Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm 2008, Texas Department of State Health Services, Austin, TX.
3. Baandrup L., Allerup P., Lublin H., Nordentoft M., Peacock L., Glenthoj B. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients. Acta Psychiatr. Scand. 2010, 122(5):367-374.
4. Bailey C.J., Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int. J. Clin. Pract. 2011, 65(3):314-322.
5. Barton J.L. A study of the effect of computer feedback on polypharmacy. J. Clin. Psychiatry 1978, 39(9):690-692.
6. Benner J.S., Chapman R.H., Petrilla A.A., Tang S.S., Rosenberg N., Schwartz J.S. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am. J. Health Syst. Pharm. 2009, 66(16):1471-1477.
7. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36(1):71-93.
8. Canadian Psychiatric Association Clinical practice guidelines. Treatment of schizophrenia. Can. J. Psychiatry 2005, 50(13 Suppl. 1):7S-57S.
9. Chong S.A., Ravichandran N., Poon L.Y., Soo K.L., Verma S. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann. Acad. Med. Singapore 2006, 35(7):457-460.
10. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. 2009, (3). (CD006324).
11. Constantine R.J., Andel R., Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment. Health J. 2010, 46(6):523-530.
12. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009, 35(2):443-457.
13. Correll C.U., Shaikh L., Gallego J.A., Nachbar J., Olshanskiy V., Kishimoto T., Kane J.M. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr. Res. 2011, 131(1-3):58-62.
14. Essock S.M., Schooler N.R., Stroup T.S., McEvoy J.P., Rojas I., Jackson C., Covell N.H. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry 2011, 168(7):702-708.
15. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J. Biol. Psychiatry 2006, 7(1):5-40.
16. Finnerty M.T., Kealey E., Leckman-Westin E., Gupta N., White T.M., Engel G.M., Opler L.A. Long-term impact of web-based tools, leadership feedback, and policies on inpatient antipsychotic polypharmacy. Psychiatr. Serv. 2011, 62(10):1124-1126.
17. Fleischhacker W.W., Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2012, 1-11.
18. Gilmer T.P., Dolder C.R., Folsom D.P., Mastin W., Jeste D.V. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr. Serv. 2007, 58(7):1007-1010.
19. Godleski L.S., Kerler R., Barber J.W., Glick J.L., Kellog E., Vieweg W.V.R., Yank G.R. Multiple versus single antipsychotic drug treatment in chronic psychosis. J. Nerv. Ment. Dis. 1989, 177(11):686-689.
20. Goren J.L., Beck S.E., Mills B.J., Shtasel D.L., Dufresne R.L. Development and delivery of a quality improvement program to reduce antipsychotic polytherapy. J. Manag. Care Pharm. 2010, 16(6):393-401.
21. Hazra M., Uchida H., Sproule B., Remington G., Suzuki T., Mamo D.C. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin. Neurosci. 2011, 65(7):676-678.
22. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br. J. Psychiatry 2005, 187:243-247.
23. Kane J.M., Leucht S., Carpenter D. The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 2003, 64(Suppl. 12):1-100.
24. Koen L., Magni P., Niehaus D.J., le Roux A. Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr. J. Psychiatry 2008, 11(4):287-290.
25. Laska E., Siegel C., Simpson G. Automated review system for orders of psychotropic drugs. Arch. Gen. Psychiatry 1980, 37(7):824-827.
26. Misawa F., Shimizu K., Fujii Y., Miyata R., Koshiishi F., Kobayashi M., Shida H., Oguchi Y., Okumura Y., Ito H., Kayama M., Kashima H. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011, 11:118.
27. National Collaborating Centre for Mental Health The NICE Guidelines on core interventions in the treatment and management of schizophrenia in primary and secondary care (update) 2010, The British Psychological Society and the Royal College of Psychiatrists, London.
28. Nielsen J., le Quach P., Emborg C., Foldager L., Correll C.U. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr. Scand. 2010, 122(5):356-366.
29. Owen R.R., Hudson T., Thrush C., Thapa P., Armitage T., Landes R.D. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. Med. Care 2008, 46(7):686-691.
30. Paton C., Lelliott P., Harrington M., Okocha C., Sensky T., Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J. Psychopharmacol. 2003, 17(2):223-229.
31. Patrick V., Schleifer S.J., Nurenberg J.R., Gill K.J. Best practices: AN initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr. Serv. 2006, 57(1):21-23.
32. Procyshyn R.M., Honer W.G., Wu T.K., Ko R.W., McIsaac S.A., Young A.H., Johnson J.L., Barr A.M. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J. Clin. Psychiatry 2010, 71(5):566-573.
33. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 2009, 360(3):225-235.
34. Robst J. Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US. PharmacoEconomics 2012, 30(5):387-396.
35. Royal Australian and New Zealand College of Psychiatrists Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust. N. Z. J. Psychiatry 2005, 39(1-2):1-30.
36. Santone G., Bellantuono C., Rucci P., Picardi A., Preti A., de Girolamo G. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol. Drug Saf. 2011, 20(5):441-449.
37. Schroeder N.H., Caffey E.M., Lorei T.W. Antipsychotic drugs: can education change prescribing practices?. J. Clin. Psychiatry 1979, 40(4):186-189.
38. Stahl S.M., Grady M.M. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr. Serv. 2006, 57(1):127-129.
39. Suzuki T., Uchida H., Tanaka K.F., Nomura K., Takano H., Tanabe A., Watanabe K., Yagi G., Kashima H. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int. J. Neuropsychopharmacol. 2004, 7(2):133-142.
40. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr. Serv. 2003, 54(1):55-59.
41. Thompson A., Sullivan S.A., Barley M., Strange S.O., Moore L., Rogers P., Sipos A., Harrison G. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial. Psychol. Med. 2008, 38(5):705-715.
42. Tsutsumi C., Uchida H., Suzuki T., Watanabe K., Takeuchi H., Nakajima S., Kimura Y., Tsutsumi Y., Ishii K., Imasaka Y., Kapur S. The evolution of antipsychotic switch and polypharmacy in natural practice-a longitudinal perspective. Schizophr. Res. 2011, 130(1-3):40-46.
43. Uchida H., Rajji T.K., Mulsant B.H., Kapur S., Pollock B.G., Graff-Guerrero A., Menon M., Mamo D.C. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J. Clin. Psychopharmacol. 2009, 29(6):571-575.
44. Ungvari G.S., Chow L.Y., Chiu H.F., Ng F.S., Leung T. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin. Neurosci. 1997, 51(5):309-314.
45. Xiang Y.T., Weng Y.Z., Leung C.M., Tang W.K., Ungvari G.S. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007, 40(2):47-52.
46. Xiang Y.T., Wang C.Y., Si T.M., Lee E.H., He Y.L., Ungvari G.S., Chiu H.F., Yang S.Y., Chong M.Y., Tan C.H., Kua E.H., Fujii S., Sim K., Yong K.H., Trivedi J.K., Chung E.K., Udomratn P., Chee K.Y., Sartorius N., Shinfuku N. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry 2012, 45(1):7-12.
47. Yoshio T. The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group. Jpn. J. Psychiatry Neurol. 2012, 114(6):690-695. (in Japanese).